symptom duration (r = 0.91, p ! 0.001) and wall motion score (r = 0.60, p = 0.006). More importantly, a strong positive association was observed between uMMA and the size of myocardial infarction in patients without successful reperfusion (for CK-MB r = 0.81, p = 0.013; for wall motion score r = 0.82, p = 0.012). Conclusion: uMMA levels were elevated in patients with AMI and, as such, may be a candidate biochemical indicator of larger infarct size and enhanced inflammation in patients with AMI.
Introduction
Methylmalonic acid (MMA) metabolism during acute myocardial infarction has not yet been thoroughly studied. Acute myocardial infarction (AMI) is likely to remain a major cause of death as the proportion of elderly people, who have a higher incidence of morbidity and mortality, increases [1] . Although methylmalonyl-CoA mutase enzyme activation has been observed during cerebral ischemia, there are limited data about urinary MMA (uMMA) levels and their clinical implications in AMI.
MMA in serum and urine is derived from the hydrolysis of D -methylmalonyl-CoA, which is a metabolic intermediate in the conversion of propionic acid to succinic acid [2] . The conversion of methylmalonyl-CoA to succinyl-CoA requires vitamin B 12 , so impaired cobalamin function causes an increased concentration of extracellular MMA [3] , which thereby becomes a sensitive marker of cobalamin status [2] . Serum MMA, however, is not a specific marker of cobalamin status because its concentrations are also elevated in renal failure, thyroid disease, small-bowel bacterial overgrowth and conditions of hemoconcentration [4] . uMMA, however, is normalized to creatinine concentrations and, therefore, corrected for both dehydration and renal insufficiency. Moreover, the measurement of uMMA is not only noninvasive but also requires only a random urine specimen [4] .
MMA may contribute to neuronal injury in many human conditions in which it accumulates, including methylmalonyl-CoA mutase and B 12 deficiency [5, 6] . Narasimhan et al. [7] demonstrated that methylmalonyl-CoA mutase is induced by several stresses, including ischemia, and this decreases the accumulation of MMA, an endogenous cellular mitochondrial inhibitor and neurotoxin.
MMA levels were found to be significantly higher in patients suffering from AMI, while the intake of vitamin B 12 was not associated with the risk of myocardial infarction [8] . However, there are few studies about the clinical significance of MMA in patients with AMI. The aim of the present study was to assess uMMA levels in patients presenting with AMI, to compare these with controls, and to determine the relationship between uMMA and other markers of myocyte necrosis and inflammation.
Subjects and Methods

Patients
The study population consisted of 80 consecutive patients with AMI (38 females and 42 males, mean age 8 SD 64 8 8 years) and 72 consecutive age-and sex-matched controls (32 females and 40 males, mean age 8 SD 61 8 8 years) drawn from those patients seen at our institution in 2002 and 2003 who were eligible for the study. In the study group, 38 patients had ST segment elevation myocardial infarction (STEMI; 24 anterior, 14 non-anterior) and 42 patients had non-ST segment elevation myocardial infarction (NSTEMI). The diagnosis of AMI was established using the American College of Cardiology/European Society of Cardiology criteria [9] .
Patients with known or proven cerebrovascular accidents, psychiatric disorders, delirium tremens, any chronic inflammatory-autoimmune disease, any neurologic disorders, renal impairment (serum creatinine 1 176.4 mol/l), known malignancy, drug ingestion which might affect B 12 metabolism, intestinal malabsorption, exocrine pancreatic insufficiency, gastrectomy, or gastritis (especially antral gastritis) were excluded from the current study.
All patients were evaluated by standard physical examination, serial resting 12-lead ECG, routine laboratory tests including serum troponin-I, creatinine phosphokinase MB band (CK-MB), high-sensitivity C-reactive protein (hs-CRP), plasma vitamin B 12 , folate, homocysteine and uMMA measurements. Of the patients with STEMI, 38 who had no contraindication to fibrinolytic treatment underwent fibrinolytic therapy. Clinical reperfusion criteria were used for assessing the efficacy of fibrinolytic treatment in patients with STEMI. Clinical reperfusion was defined as complete resolution of chest pain, run of accelerated idioventricular rhythm and a decrease of at least 70% in ST segment elevation on surface ECG at 90 min after fibrinolytic therapy.
Blood Sampling and Urine Collection
Blood samples for the determination of cardiac enzymes (CK and CK-MB fraction, GPT and LDH) and markers (troponin-I) were collected at hospital admission and at 8-hour intervals, until 2 consecutive drops in CK-MB activity were obtained.
Blood samples for the measurement of vitamin B 12 and hs-CRP were taken at hospital admission. Urine samples of patients with AMI were collected over 8 h by means of transurethral catheters upon admission; urine from the control group was collected in the morning.
Urine MMA Measurement Method
The uMMA measurements were made based on a modified photometric method [10] that utilized a scanning spectrophotometer (UV/VIS scanning spectrophotometer, PU 8700 series, Philips, UK). This method is based on the reaction between methylmalonic acid and diazotizated p -nitroaniline.
Other Laboratory Analyses
Serum vitamin B 12 , folate, CK-MB and troponin-I measurements were made using automated immunoassays using the Abbott IMx analyzer (Abbott Laboratories, Chicago, Ill., USA). Plasma total homocysteine levels were determined by high performance liquid chromatography with fluorescence detection using a commercial assay (Chromosystems, Munich, Germany). Serum hs-CRP measurements were made using the nephelometric method and Beckman Array nephelometry.
Echocardiography
Transthoracic echocardiography was performed using the VingMed System Five echocardiographic system (GE Medical Systems, Horten, Norway) at the left lateral decubitis position after fibrinolytic treatment. Left ventricular ejection fraction was calculated using Simpson's rule. Wall motion of 16 myocardial segments was interpreted according to the criteria of the American Society of Echocardiography [11] . The wall thickening of each myocardial segment was scored as follows: normokinesia or hyperkinesia = 0; hypokinesia = 1; severe hypokinesia = 2; akinesia = 3; dyskinesia = 4. The wall motion score was calculated as the sum of the scores within the area at risk.
Statistical Analysis
Results are expressed as the mean 8 SD, median (minimum to maximum) and percentages. Kolmogorov-Smirnov and Levene tests were used to determine the distribution characteristics of variables and variance homogenity. With respect to these test results, we used independent sample t tests or Mann-Whitney U tests as appropriate. Differences between control and patient groups were tested for significance by 2 
Results
Comparison of baseline clinical characteristics of patients with AMI and those of controls showed that several classical risk factors were found to be significantly higher in patients with AMI than controls (p ! 0.05) but not smoking, age, gender or BMI ( table 1 ) . Analysis of biochemical parameters showed that troponin-I, plasma peak CK-MB, hs-CRP and uMMA levels were significantly higher in patients with AMI than the controls ( table 2 ). More importantly, uMMA levels were higher in patients with AMI than in controls [median (min.-max.) 10.1 (3.1-29.3) vs. 5.2 (2.6-7.9) mmol/mol creatinine, p ! 0.001].
A moderately positive association was found between plasma hs-CRP (r = 0.56, p ! 0.001), peak plasma CK-MB (r = 0.47, p = 0.019) and troponin-I levels (r = 0.54, p ! 0.001) and uMMA levels in patients with AMI ( fig. 1 ) . A good positive correlation was found between uMMA and wall motion score (r = 0.65, p ! 0.001) and symptom duration (r = 0.90, p ! 0.001). There was also a negative association between uMMA and left ventricular ejection fraction (LVEF; r = -0.61, p ! 0.001) in patients with AMI.
Analysis of the patients with STEMI showed a strong positive association between uMMA and plasma hs-CRP levels (r = 0.81, p ! 0.001), symptom duration (r = 0.91, p ! 0.001) and wall motion score (r = 0.60, p = 0.006). Also, a strong negative correlation was found between uMMA levels and LVEF (r = -0.75, p ! 0.001). uMMA levels in patients with STEMI were found to be higher compared to those of the patients with NSTEMI [ Complete clinical reperfusion was achieved in 24 patients after fibrinolytic treatment. Strong positive associations were observed between uMMA levels, CK-MB (r = 0.81, p = 0.013) and wall motion score (r = 0.82 p = 0.012) in patients without successful clinical reperfusion. Besides, a strong positive correlation was detected between uMMA levels and symptom duration in patients with clinical reperfusion (r = 0.91, p ! 0.001). Also, uMMA levels were significantly lower in patients with clinical reperfusion compared to those patients without clinical reperfusion [ table 4 : median (min.-max.) 9.9 (3.7-29.3) vs. 21.1 (15.5-28.7) mmol/mol creatinine, p = 0.002)].
Examination of uMMA levels in patients with STEMI based on infarction location demonstrated that uMMA levels were higher in patients with anterior myocardial infarction compared to those with non-anterior myocar- 
Discussion
The current study reveals that uMMA levels were elevated in patients with AMI compared to those of controls. Moreover, uMMA levels were found to be higher in patients without clinical reperfusion than patients in whom clinical reperfusion was achieved.
The conversion of methylmalonyl-CoA to succinylCoA requires vitamin B 12 , therefore a deficiency of vitamin B 12 increases the concentration of MMA [12] . Although vitamin B 12 showed no clear association with AMI, the levels of MMA were reported to be higher in patients with AMI [7] . In fact, uMMA concentrations often increase in the early stages of vitamin B 12 deficiency before measurable decreases in serum vitamin B 12 are evident at the tissue level [13] . In the current study, serum vitamin B 12 levels of patients with AMI were not different from those of the controls. However, uMMA levels were significantly higher in patients with AMI compared with those of controls. Therefore, it may be a plausible to suggest that one of the mechanisms resulting in the increase of MMA in patients with AMI might be B 12 deficiency at a myocardial tissue level during myocardial ischemia. On the other hand, deficiency of vitamin B 12 and folate are frequently seen in elderly individuals [14] [15] [16] [17] [14, 15] . Therefore, functional vitamin B 12 deficiency may be encountered in the elderly, especially in the very old (age 1 80 years). So, it is probable that functional B 12 deficiency in our study population might have increased their uMMA levels. However, our study population and control patients were of similar age, and all were in the 'young-old' age range. Plasma homocysteine levels were not different in patients with AMI compared to controls. It is known that the concentrations of homocysteine in serum and plasma are elevated in both folate and vitamin B 12 deficiencies, whereas MMA in serum, plasma or urine is a specific marker of vitamin B 12 function [3] . From that point of view, it is possible that deficiency of vitamin B 12 at tissue level during myocardial ischemia may result in increased uMMA.
The increased uMMA levels in patients with STEMI in whom complete clinical reperfusion was not achieved led us to consider that ongoing myocardial ischemia may be associated with increased uMMA. Increased uMMA levels may, therefore, be a new complementary marker of unsuccessful reperfusion treatment. Contrary to brain ischemia, methylmalonyl-CoA mutase enzyme activity in the heart may be inhibited during myocardial ischemia, although that needs experimental evidence.
In the present study, a strong positive correlation was found between uMMA and hs-CRP in patients with AMI. It was previously reported that an elevated serum hs-CRP level was related to a worse clinical outcome, including pump failure, atrial fibrillation and left ventricu- [18] [19] [20] . Also, CRP is not only a marker of the amount and activity of circulating proinflammatory cytokines, it may also contribute to inflammation in ischemic myocardium by activating the complement system [21] . Although the data obtained from the current study imply that increased uMMA concentrations in AMI may be a secondary phenomenon to enhanced hs-CRP, there has been no report to date indicating whether enhanced inflammation causes an increase of uMMA. The presence of a strong relationship between uMMA levels and symptom duration time led us to conclude that increased uMMA levels may be one of the time-dependent markers of ongoing myocardial necrosis. From that standpoint, it is possible that admission uMMA might be another new marker of ongoing myocardial necrosis and inflammation in the area supplied by the infarct-related artery in patients with AMI. We also found an association between uMMA levels and markers of infarction size such as peak CK-MB, troponin-I concentrations, wall motion score and LVEF in patients with AMI. These findings suggest that uMMA levels may also be related to infarct size. The design and size of the present study do not allow us to draw a conclusion on a temporal relationship between an AMI event and MMA excretion in urine. Assay of methylmalonyl-CoA mutase enzyme activity in the study groups and monitoring of uMMA in patients with AMI some time after infarction would also have been helpful in that regard.
Conclusion
uMMA levels are increased in patients with AMI. uMMA warrants further investigation as a potential biochemical indicator of larger infarct size, enhanced inflammation and of incomplete reperfusion in these patients.
